Last reviewed · How we verify
Placebo Gefitinib
Placebo Gefitinib is a Small molecule drug developed by Nanjing Sanhome Pharmaceutical, Co., Ltd.. It is currently in Phase 3 development for Control arm in gefitinib clinical trials (Phase 3). Also known as: Gefitinib (Iressa).
This is a placebo control arm, not an active drug, and contains no therapeutic mechanism.
This is a placebo control arm, not an active drug, and contains no therapeutic mechanism. Used for Control arm in gefitinib clinical trials (Phase 3).
At a glance
| Generic name | Placebo Gefitinib |
|---|---|
| Also known as | Gefitinib (Iressa) |
| Sponsor | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebo Gefitinib refers to an inactive control formulation used in clinical trials to compare against active gefitinib treatment. It contains no active pharmaceutical ingredient and produces no pharmacological effect. The placebo arm allows researchers to isolate the true efficacy of gefitinib by controlling for patient expectation and natural disease progression.
Approved indications
- Control arm in gefitinib clinical trials (Phase 3)
Common side effects
Key clinical trials
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (PHASE3)
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） (PHASE3)
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) (PHASE3)
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients (PHASE3)
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC (PHASE3)
- Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (PHASE3)
- A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Gefitinib CI brief — competitive landscape report
- Placebo Gefitinib updates RSS · CI watch RSS
- Nanjing Sanhome Pharmaceutical, Co., Ltd. portfolio CI
Frequently asked questions about Placebo Gefitinib
What is Placebo Gefitinib?
How does Placebo Gefitinib work?
What is Placebo Gefitinib used for?
Who makes Placebo Gefitinib?
Is Placebo Gefitinib also known as anything else?
What development phase is Placebo Gefitinib in?
Related
- Manufacturer: Nanjing Sanhome Pharmaceutical, Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Control arm in gefitinib clinical trials (Phase 3)
- Also known as: Gefitinib (Iressa)
- Compare: Placebo Gefitinib vs similar drugs
- Pricing: Placebo Gefitinib cost, discount & access